Pain Management · Local AnestheticsSafety Signalcommercialnear-term

Medline Issues Correction for Convenience Kits Containing Recalled Lidocaine and Bupivacaine

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/4/2026, 6:01:53 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The recall of Lidocaine and Bupivacaine from Medline's convenience kits could disrupt the supply of local anesthetics, impacting clinical practices and competitive dynamics in the pain management sector. Portfolio teams need to evaluate the potential effects on product availability and strategize accordingly. Regulatory context from FDA (Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection) supports the near-term read. Assessment grounded in 9 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on product availability and consider strategies to mitigate supply chain disruptions. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 2 competitive items passed relevance filtering for Medline.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Pregabalin Application ANDA219593 by Unichem (Humanexa Signals) — sub-indication match (pain). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This recall may impact the availability of local anesthetics in clinical settings, potentially affecting competitors in the pain management market.

Regulatory Outlook

Regulatory risk is concentrated around Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection (FDA). Entity match (medline). The FDA's involvement in the recall indicates potential regulatory scrutiny, which could affect compliance and approval processes for similar products in the future.

Key Risks

Elevated medium regulatory exposure for Medline could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This recall may lead to temporary shortages in local anesthetics, affecting market share and revenue for companies reliant on these products. Competitors may need to adjust their strategies to capitalize on potential gaps in supply.
Portfolio teams should assess the impact of this recall on product availability and consider strategies to mitigate supply chain disruptions.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall status and any potential regulatory actions from the FDA.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection
FDAmedium relevance
Entity match (medline)
FDA document
View source
Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP
FDAmedium relevance
Entity match (medline)
FDA document
View source
Convenience Kit Correction: Arrow International Issues Correction for Convenience Kits Containing Recalled Huons Lidocaine and Bupivacaine and Saline
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Convenience Kit Correction: Medical Action Industries Issues Correction for Kits Containing Recalled Namic Manifolds
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Convenience Kit Correction: Windstone Medical Packaging, Inc.
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Infusion Pump Correction: Fresenius Kabi Issues Correction for Ivenix Large Volume Infusion Pump
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Development of Pain Control Options Menu for IUD Insertion
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Preoperative Dexamethasone Injection to Improve Local Anesthesia Success in Endodontic Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of Dry Needling Plus Vibration on Myofascial Trigger Points in Individuals With Nonspecific Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pain Neuroscience Education for Chronic Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approves Pregabalin Application ANDA219593 by Unichem
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Resmed Issues Correction for Astral Ventilator Due to Electrical Component Failure
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Liposomal bupivacaine versus ropivacaine for surgical site infiltration in lumbar fusion: a prospective randomized controlled trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of different liposomal bupivacaine concentrations in ultrasound-guided superior trunk block on postoperative analgesia and mobility: a randomized double-blind controlled trial protocol for shou
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Management of uterine fibroids: opinions on interventions and the future of services in the United Kingdom-a pilot survey.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Medline
Huons Lidocaine Hydrochloride
Bupivacaine Hydrochloride

Commercial impact

medium

This recall may lead to temporary shortages in local anesthetics, affecting market share and revenue for companies reliant on these products. Competitors may need to adjust their strategies to capitalize on potential gaps in supply.

Regulatory impact

medium

The FDA's involvement in the recall indicates potential regulatory scrutiny, which could affect compliance and approval processes for similar products in the future.

What to watch

Monitor for updates on the recall status and any potential regulatory actions from the FDA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.